How much cash does Capricor Therapeutics generate?

Capricor Therapeutics (CAPR) generated -$92.6M in operating cash flow over the trailing twelve months.

What is Capricor Therapeutics's free cash flow?

After $7.1M of capital expenditures, Capricor Therapeutics's free cash flow was -$99.8M over the trailing twelve months, down 114.0% year over year.

Where does Capricor Therapeutics's cash flow data come from?

Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Capricor Therapeutics CAPR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$105.04M-160%	-$40.47M-81.6%	-$22.29M+23.2%	-$29.02M-44.9%
Depreciation and amortization	$1.89M+32.5%	$1.43M+33.3%	$1.07M+100%	$533.13K+117%
Stock-based compensation	$16.97M+73.8%	$9.77M+32.1%	$7.39M+65.8%	$4.46M+50.3%
Change in accrued liabilities	$5.98M+208%	$1.94M—	——	——
Change in other assets	$4.09M+793%	$458.65K+504%	$75.88K—	——
Other working capital changes	——	——	——	——
Net cash from operating activities	-$69.81M-74.5%	-$40M-56.3%	-$25.6M—	——
Capital expenditures	$2.9M+149%	$1.17M-11.0%	$1.31M-34.4%	$2M+67.2%
Net cash from investing activities	$97.48M+184%	-$116.18M—	——	——
Proceeds from issuance of common stock	$237.03M+55.6%	$152.32M+497%	$25.52M+431%	$4.8M-76.2%
Net cash from financing activities	$248.89M+62.9%	$152.77M+497%	$25.58M+425%	$4.87M-75.9%
Net increase (decrease) in cash	——	——	——	-$26.47M—
Amortization Or Accretion Of Debt Discount Premium	——	——	——	——
Increase Decrease From Grants Receivable	-$10.31M—	——	——	——
Other current liabilities	$5.98M+208%	$1.94M—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$4.09M+793%	$458.65K+504%	$75.88K—	——
Noncash Lease Expenses	$715.46K+1,614%	-$47.26K-94.6%	-$24.28K-114%	$168.25K+248%
Other Noncash Income (Expense)	——	——	——	——
Stock-based compensation expense — restricted shares	——	$0—	——	——
Stock Option Plan Expense	$16.97M+73.8%	$9.77M—	——	——
Payments For Construction In Progress	——	$0—	——	——
Payments To Acquire Leasehold Improvements	$383.54K+3.1%	$372.1K-49.4%	$735.87K-45.9%	$1.36M—
Interest Expense, Nonoperating	$3.05M—	$0—	——	——
Free cash flow	-$72.72M-76.7%	-$41.16M-53.0%	-$26.91M—	——
Free cash flow	-$72.72M-76.7%	-$41.16M-53.0%	-$26.91M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Capricor Therapeutics generate?: Capricor Therapeutics (CAPR) generated -$92.6M in operating cash flow over the trailing twelve months.
What is Capricor Therapeutics's free cash flow?: After $7.1M of capital expenditures, Capricor Therapeutics's free cash flow was -$99.8M over the trailing twelve months, down 114.0% year over year.
Where does Capricor Therapeutics's cash flow data come from?: Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.